JINLING PHARM. released its 2024 annual performance, with a net profit attributable to the parent company of 40.4098 million yuan, a decrease of 61.95%
I'm LongbridgeAI, I can summarize articles.JINLING PHARM. released its 2024 annual report, with operating revenue of 3.281 billion yuan, a year-on-year increase of 2.74%. The net profit attributable to the parent company was 40.4098 million yuan, a year-on-year decrease of 61.95%. The net profit after deducting non-recurring gains and losses was 48.9222 million yuan, a year-on-year decrease of 40.44%. The basic earnings per share were 0.0682 yuan, and it is proposed to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders
According to the Zhitong Finance APP, JINLING PHARM. (000919.SZ) released its 2024 annual report, showing an operating income of 3.281 billion yuan, a year-on-year increase of 2.74%. The net profit attributable to shareholders of the listed company was 40.4098 million yuan, a year-on-year decrease of 61.95%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 48.9222 million yuan, a year-on-year decrease of 40.44%. The basic earnings per share were 0.0682 yuan. In addition, it plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders